After 5 days of treatment (100 mg/kg daily), hepatic triglycerides were increased and both microvesicular steatosis and ultrastructural mitochondrial lesions were present.
In conclusion, glucocorticoids inhibit mediumand short-chain acyl-CoA dehydrogenation and hepatic lipid secretion in mice. These effects may account for their steatogenic effects in humans.
hepatic lipid secretion; steatosis; steatohepatitis P-oxidation enzymes (valproate, tetracyclines, nonsteroidal anti-inflammatory agents with an aryl-2-propionate structure, tricyclic antidepressants with a heptanoic side chain, or cationic amphiphilic drugs that accumulate within mitochondria) (4, 6-10, 12, 14, 19-21).
Even mild forms of microvesicular and/or macrovacuolar steatosis, although well tolerated in the short term, can cause damage in the long term. In some patients with prolonged steatosis, severe steatohepatitis lesions may develop (13). In addition to steatosis, liver lesions then associate hepatocyte necrosis, Mallory bodies, neutrophilic inflammatory cell infiltrates, and liver fibrosis (13). In severe forms, this fibrotic process may lead to cirrhosis and death (13). Although the mechanism for these steatohepatitis lesions remains uncertain, several recent studies have suggested a possible mediation by steatosis-induced chronic lipid peroxidation (23, 24) .
Prolonged administration of high doses of glucocorticoids is known to cause hepatic steatosis and even steatohepatitis lesions in humans (17). However, the molecular mechanisms responsible for these acute and chronic effects have not been determined.
HEPATIC STEATOSIS IS considered a relatively benign liver lesion. Although this reputation may be valid for mild forms and for short-term disease, it may not apply in other conditions. Extensive microvesicular steatosis is now recognized as the histological hallmark of severe metabolic diseases that can result in multiorgan failure, coma, and death within a few days (13). This condition occurs whenever the mitochondrial P-oxidation of fatty acids is severely impaired (13). This may be caused by inborn errors affecting ureagenesis (25), the mitochondrial respiratory chain (28), or the transporters or enzymes involved in mitochondrial P-oxidation (1, 2, 31). The condition may also be acquired. Endogenous substances or drugs may terminate the replication of mitochondrial DNA (dideoxynucleosides used in the treatment of the human immunodeficiency virus infection) (30), cause oxidative damage to mitochondrial DNA (ethanol abuse) (11, 32), or decrease the transcription of mitochondrial DNA (interferon-a) (29). Endogenous substances or drugs may also cause ultrastructural and functional lesions of mitochondria (female sex hormones) (15, 16), sequester CoA (aspirin, valproate) (5,19), and/or directly inhibit mitochondrial After being activated into acyl-CoA thioesters and transported into the mitochondria through the carnitine shuttle, long-chain fatty acids then undergo the P-oxidation process (26). The first step in the mitochondrial P-oxidation cycle is mediated by acyl-CoA dehydrogenases (26). Four different enzymes catalyze the initial dehydrogenation of straight-chain fatty acids in mitochondria (2). The first enzyme, termed very-longchain acyl-CoA dehydrogenase (VLCAD), is attached to the inner membrane; it functions as a homodimer, and the VLCAD monomer exhibits little sequence homology with those of the three other dehydrogenases (2,18). In contrast, the long-, medium-, and short-chain acyl-CoA dehydrogenases (LCAD, MCAD, and SCAD, respectively) are soluble enzymes located in the mitochondrial matrix; they function as homotetramers, and the LCAD, MCAD, and SCAD monomers exhibit extensive sequence homologies (2). Despite its name, purified VLCAD is also extremely active with long-chain fatty acids (18), making the activity of LCAD largely redundant (26). VLCAD, followed by the trifunctional enzyme of the inner mitochondrial membrane, may mediate most of the shortening of long-chain fatty acids into medium-chain fatty acids (26). The latter are then handled by MCAD, SCAD, and other soluble P-oxidation enzymes of the mitochondrial matrix (26). In vitro mitochondrial p-oxidation. Liver mitochondria (l-2 mg protein/2 ml) were incubated at 30°C for 10 min with the [14C]fatty acid (40 PM), ATP (0.2 mM), L-carnitine (40 PM), and CoA (40 PM), with or without KCN (2 mM), as described (15). The reaction was stopped by adding 0.4 ml of 5% perchloric acid into the incubation mixture. After centrifugation, the 14C-labeled acid-soluble P-oxidation products were measured as previously described (10). These products mainly represent ketone bodies and to a small extent citric acid cycle intermediates (10). Mitochondrial activity was calculated as the KCN-inhibitable activity. AcyZ-CoA dehydrogenases.
The activities of VLCAD, LCAD, MCAD, and SCAD were determined by spectrophotometric assay using ferricenium hexafluorophosphate as an alternative reoxidant that mimics electron transfer flavoprotein (22). To determine the activity of the soluble enzymes (LCAD, MCAD, and SCAD), mitochondria were frozen, thawed, and sonicated in ice. Membrane-bound enzymes were centrifuged at 100,000 g for 60 min at 4"C, and the supernatant (soluble enzymes) was recovered. An aliquot (100 pg protein) was added to 800 ~1 of sodium phosphate buffer, pH 8, at 37°C containing ferricenium hexafluorophosphate (200 PM), N-ethylmaleimide (500 PM), and EDTA (0.1 PM). In the standard assay, the reaction was started by adding palmitoylCoA, octanoyl-CoA, or butyryl-CoA (100, 50, and 50 PM, respectively).
The activity of the acyl-CoA dehydrogenase was determined by following the initial decrease in absorbance at 290 nm due to the reduction of the ferricenium salt (15). To determine inhibition kinetics, MCAD and SCAD activities were measured in the presence of various concentrations of substrate and various concentrations of dexamethasone. The activity of membrane-bound VLCAD was first determined as follows. To further eliminate soluble enzymes from the 100,000 g pellet that had been prepared as described above, this pellet was submitted to four additional cycles of sonication, centrifugation, and resuspension. Elimination of most soluble enzymes from the final pellet was ascertained by showing that the specific activity of SCAD in this pellet was reduced to one-tenth of its specific activity in the initial supernatant.
The activity of VLCAD toward palmitoyl-CoA was then determined with 100 pg protein in the test cuvette, as described above.
In . In fasted mice, the increase in plasma triglycerides after the administration of Briton WR-1339 reflects the secretion of triglycerides by the liver (20). Twenty-four-hour fasted mice were anesthetized with diethyl ether and received 0.3 ml of a solution of Triton WR-1339 (100 mg/ml) in isotonic saline, injected in a tail vein. Plasma triglycerides were determined using a commercial kit (Biotrol A 01549, Chennevieres-LesLouvres, France) before and 3 h after the administration of Triton WR-1339.
Hepatic triglycerides and liver morphology. Mice were killed 24 h after the last dose of dexamethasone 21-phosphate (100 mg/kg once daily for 5 days). Hepatic lipids were extracted in 3 vol of chloroform-methanol (2:1, vol/vol), and triglycerides were determined using a commercial kit (Sigma kit 405) as previously reported (14).
For light microscopy, one liver fragment was fixed with formaldehyde for hematoxylin and eosin staining, whereas the other fragment was snap-frozen in liquid nitrogen, cut with a cryostat, and stained with oil red 0.
For electron microscopy, l-mm3 liver fragments were fixed with glutaraldehyde and osmium tetroxide and embedded in epoxy resins after dehydration.
Ultrathin sections stained with uranyl acetate and lead citrate were examined with a JEOL 1010 electron microscope (JEOL, Tokyo, Japan).
StatisticaL anaZysis. The Student's t-test for independent data or analysis of variance followed by a Dunnett's t-test were used to assess the significance of differences between means, as appropriate.
RESULTS

Ex vivo and in vitro effects of dexamethasone on the
acid is labeled on all carbons. When this labeled fatty acid is P-oxidized by mitochondria, all successive P-oxidation cycles produce 14C-labeled p-oxidation products. The measurement of these products serves as a global test that can detect enzyme inhibitions affecting the P-oxidation of either long-or medium-and short-chain fatty acids (13).
Mitochondria were isolated from control mice or mice killed at various times after the administration of dexamethasone 2Lphosphate (100 mg/kg), and their ability to P-oxidize [UJ4C]palmitic acid was compared (Table 1) . Mitochondrial P-oxidation was decreased by 44% 10 min after dexamethasone administration (Table  1) ; P-oxidation was not significantly modified 1,3,14, or 24 h after dexamethasone administration (Table 1 ). These observations suggested that dexamethasone exerted an immediate, but rapidly reversible, inhibitory effect on mitochondrial P-oxidation. Repeated doses of dexamethasone produced effects that were similar to those of a single dose (Table l) , indicating an absence of cumulative effects.
In vitro, the addition of dexamethasone 21-phosphate to hepatic mitochondria from control mice inhibited the formation of 14C-labeled P-oxidation products from [U-14C]palmitic acid. This formation (mean t SE for 4 experiments) was 10.1 t 0.5 nmol min-l l mg mitochondrial protein-l in the control incubation but 7.1 t 0.3 nmol l min-l l mg mitochondrial protein with 20 ,uM dexamethasone (P < 0.01).
In vitro effects of dexamethasone on mitochondrial respiration. Because severe impairment of the mitochondrial respiratory chain may lead to secondary inhibition of mitochondrial P-oxidation (13), we first determined the effects of dexamethasone on mitochondrial respiration. However, dexamethasone 21-phosphate (20 JJM) had only limited effects on the respiration of mouse liver mitochondria (Table 2) , excluding this mechanism as the cause for the impaired P-oxidation.
In vitro effects of dexamethasone on the mitochondrial P-oxidation of [l J4C]fatty acids.
[ 1J4C]fatty acids are only labeled on the carboxylic carbon. With these labeled fatty acids, only the first P-oxidation cycle forms 14C-labeled P-oxidation products. Accordingly, the formation rate of 14C-labeled P-oxidation products is lower (Fig. 1 ) than with an [UJ4C]fatty acid (Table 1) . By using [ lJ4C]fatty acids of various chain lengths, one can determine whether the inhibition affects enzymes that handle either long-, medium-, or short-chain fatty acids (13). Dexamethasone (20 PM) had no effect on the first P-oxidation cycle of [ lJ4C]palmitic acid but inhibited that of [1-14C]octanoic acid and [lJ4C]butyric acid ( Fig.  1) , indicating that dexamethasone inhibited enzymes handling medium-and short-chain fatty acids. In vitro effects of dexamethasone on various fatty acyl-CoA dehydrogenases. These enzymes mediate the first step in the P-oxidation cycle (26). When a longchain fatty acid is P-oxidized in mitochondria, the fatty acid is initially handled by the VLCAD and the trifunctional enzyme of the mitochondrial inner membrane (making the activity of soluble LCAD largely redundant) (26). The chain-shortened fatty acid is then successively handled by MCAD and SCAD in the matrix (26). The activity of VLCAD was measured in the mitochondrial membrane fraction, whereas those of LCAD, MCAD, and SCAD were determined in the mitochondrial matrix fraction (Fig. 2) . MCAD and SCAD specific activities in control incubations (Fig. 2) were much higher than the formation rate of 14C-labeled P-oxidation products from [ lJ4C]octanoic acid or [lJ4C]butyric acid (Fig. 1) . However, MCAD and SCAD activities are expressed per proteins of a relatively purified fraction (matrix proteins), whereas p-oxidation products are expressed per proteins of a much larger protein pool (total mitochondrial proteins). Furthermore, MCAD and SCAD activities represent a single enzymatic step, whereas the formation of 14C-labeled P-oxidation products requires a large number of successive steps, namely, entry of the fatty acid in Fig. 1 Octanoate Butyrate mitochondria, activation into the acyl-coenzyme thioester, the four successive steps of the P-oxidation cycle, and finally, formation of ketone bodies (the main p-oxidation products). Dexamethasone (20 PM) inhibited the activity of soluble LCAD, MCAD, and SCAD by 49,45, and 84%, respectively (Fig. 2) . Inhibition kinetics were consistent with competitive inhibition of SCAD and mixed inhibition of MCAD by dexamethasone (Fig. 3) .
In contrast, dexamethasone (20 PM) did not inhibit the activity of the membrane-bound VLCAD, measured with palmitoyl-CoA in a mitochondrial membrane fraction (Fig. 2) . VLCAD activity was also measured with docosanoyl-CoA (Table 3) . This very-long-chain fatty acid (C,,) is selectively dehydrogenated by VLCAD, without involvement of LCAD (18). This specific fatty acid allows measurement of VLCAD activity not only in the mitochondrial membrane fraction but also directly in whole mitochondria (Table 3) SCAD expression in mice, enzyme activities were mea- (Fig. 4) . In vivo effects of dexamethasone on the hepatic secretion of triglycerides. The hepatic secretion of triglycerides was assessed from the increase in plasma triglycerides after interrupting the hepatic and peripheral utilization of triglycerides by the administration of Triton WR-1339 (tyloxapol) in 24-h fasted mice. Under these conditions, the progressive increase in plasma triglycerides reflects their hepatic synthesis (20). sured in mitochondrial matrix proteins prepared from either control mice or mice killed at various times after administration of dexamethasone phosphate. Despite the multiple washings involved in the preparation of isolated mitochondria and matrix proteins, some of the dexamethasone that is present in the liver at the time of death may stick to matrix enzymes and inhibit them. Accordingly, any reduction in activity may correspond to either residual inhibition or reduced expression. MCAD activity was decreased by 39% 10 min after dosing, 14% at 14 h, and 4% at 24 h (Table 5) . SCAD activity was decreased by 30% at 10 min, 15% at 14 h, and 17% at 24 h (Table 5 ). The small decreases observed at late times indicated that any effects of dexamethasone on MCAD or SCAD expression remained at most very moderate.
Three hours after administration of Triton WR-1339, plasma triglycerides reached 23 times the pre-Triton values in mice not treated with dexamethasone (Fig. 5) . In contrast, plasma triglycerides only increased to four times the pre-Triton value in mice treated with dexamethasone 21-phosphate (100 mg/kg) 30 min before the administration of Triton WR-1339 (Fig. 5) , indicating that this treatment decreased the hepatic secretion of triglycerides.
Effects of prolonged treatments with dexamethasone on hepatic lipids and hepatic morphology. Administration of dexamethasone 21-phosphate (100 mg/kg for 5 days) increased the liver weight-to-body weight ratio by 40% (mean t SE for 8 mice, 5.7 t 0.9% in control mice vs. 8.0 ~fr 0.6% in treated mice), increased hepatic lipids by 44% (48 t 2 mglg liver in control mice vs. 69 IT 5 mglg liver in treated mice), and increased hepatic triglycerides by 133% (9 t 1 mg/g liver in control mice vs. 21 t 3 mglg liver in treated mice).
In vivo effects of dexamethasone and other glucocorticoids on the oxidation of [1-14C]fatty acids. These labeled fatty acids were administered by gastric intubation 10 min after the intraperitoneal administration of dexamethasone 21-phosphate (100 mg/kg), and the exhalation of [14C]COZ was measured. Because these fatty acids are labeled only on the first carbon, only the first P-oxidation cycle produces [14C]C02. The oxidation of [1-14C]palmitic acid into [14C]C02 was not inhibited, After oil red 0 staining, light microscopy showed massive microvesicular steatosis of the liver (data not shown). On electron microscopy, hepatocytes from control mice had a normal ultrastructural appearance (Fig. 6A) . In dexamethasone-treated mice, the main abnormality was the presence of numerous lipid droplets of various size in almost all hepatocytes (Fig. 6B) . Hypertrophic and elongated mitochondria were visible in most hepatocytes (Fig. 6B) . Vesiculation of the endoplasmic reticulum was observed in many cells (Fig. 6B) . 
DISCUSSION
Although glucocorticoids are known to be steatogenic agents in humans (17), the mechanism for this effect has not been determined. The present results show that dexamethasone inhibits the mitochondrial P-oxidation of fatty acids (Table 1 , Fig. 1 ) and the hepatic secretion of triglycerides (Fig. 5) , thus causing microvesicular steatosis of the liver in mice (Fig. 6B ).
After being activated into acyl-CoA thioesters that are transported into the mitochondria through the carnitine shuttle, long-chain fatty acids then undergo the P-oxidation process (26). The first step in the mitochondrial P-oxidation cycle is mediated by acylCoA dehydrogenases (26). Four different enzymes cata-
Control mice
Dexamethasone-treated mice lyze the initial dehydrogenation of straight-chain fatty acids in mitochondria (2). Whereas LCAD, MUD, and SCAD all exhibit extensive sequence homologies, are soluble enzymes of the mitochondrial matrix, and function as homotetramers, in contrast, VLCAD has limited sequence homology with these soluble enzymes, is attached to the inner mitochondrial membrane, and functions as a homodimer (2). These homologies (LCAD, MCAD, and SCAD) and differences (VLCAD) may explain why dexamethasone inhibited LCAD, MCAD, and SCAD, without inhibiting VLCAD (Fig. 2, Table 3 ). The kinetics of inhibition were assessed with SCAD and MCAD and found to be consistent with competitive inhibition and mixed inhibition, respectively (Fig. 3) . This may suggest that the steroid may displace the fatty acid from the active site of the matrix dehydrogenase.
We compared the inhibitory effects of various steroids (20 PM) on MCAD activity (Table 4) . Aldosterone and the seven glucocorticoids that were studied all inhibited MCAD by 45% or more (Table 4) . These steroids have a basal 21-hydroxy-pregn-4-ene-3,20-dione structure in common. In contrast, estradiol and progesterone exerted mild inhibitory effects, whereas testosterone had no effect (Table 4) . Estradiol and testosterone do not have the 20,21-side chain of pregnane steroids, whereas no 21-hydroxyl group is present in the pregnane derivative progesterone. More extensive structure-activity studies are needed to characterize the structural factors that govern the variable inhibitory potency of various steroids.
Despite its name, VLCAD is extremely active with long-chain fatty acids (l&26). When a long-chain fatty acid is p-oxidized in mitochondria, the fatty acid is first handled by VLCAD and then the trifunctional enzyme of the mitochondrial inner membrane, making the activity of soluble LCAD largely redundant (26). Dexamethasone, which inhibited LCAD but not VLCAD (Fig. 2, Table 3 ), did not inhibit the formation of 14C-labeled P-oxidation products when hepatic mitochondria were incubated with [ lJ4C]palmitic acid (Fig.  1) . In this fatty acid, only the carboxylic carbon is 14C-labeled. Therefore, only the first P-oxidation cycle produces 14C-labeled P-oxidation products. Failure of dexamethasone to inhibit this first P-oxidation cycle (Fig. 1) indicates that neither VLCAD nor the trifunctional enzyme is inhibited. This was further confirmed in vivo (Fig. 4) . Administration of dexamethasone 21-phosphate (100 mg/kg) did not inhibit the formation of [ 14C]C02 afte r administration of [ lJ4C]palmitic acid (Fig. 4) . Only the first P-oxidation cycle of [1J4C]palmitic acid eventually produces [14C]C02 because this fatty acid is only labeled on the carboxylic carbon.
Once the long-chain fatty acid has been chainshortened by inner membrane-bound enzymes, it is then successively handled by MCAD and SCAD in the mitochondrial matrix (26). Dexamethasone, which inhibited MCAD and SCAD (Figs. 2 and 3) , inhibited the first P-oxidation cycle of [1-14C] (Fig. 4) . Interestingly, dexamethasone also inhibited the ex vivo formation of 14C-labeled products with [U-14Clpal-mitic acid (Table 11 , which is labeled on all carbons and therefore produces 14C-labeled products during all successive p-oxidation cycles. With this fatty acid, the first P-oxidation cycle is not inhibited (as explained above), but further P-oxidation cycles then become inhibited once the fatty acid has been chain-shortened to medium-and short-chain fatty acids. Dexamethasone administration has been reported to decrease the mRNAs for SCAD, MCAD, and LCAD in the liver of rats killed 14 h later, but protein levels or enzyme activities were not determined (27). In the present study, P-oxidation (Table 1) and MCAD or SCAD activities (Table 5) were only moderately decreased 14 or 24 h after dexamethasone administration, indicating that any effect of dexamethasone on MCAD or SCAD expression was at most very moderate.
Instead, the in vivo impairment of fatty acid oxidation (Fig. 4) (Fig. 3) . This severe inhibition may account for the reduced oxidation of fatty acids in vivo (Fig. 4) . Indeed, MCAD or SCAD deficiencies markedly decrease P-oxidation in humans (1, 26, 31) .
When the P-oxidation of fatty acids is severely impaired, nonesterified fatty acids increase in the liver and undergo increased esterification into triglycerides (13). The latter can either be secreted as lipoproteins or accumulate as small lipid vesicles within hepatocytes (13). Administration of dexamethasone impaired not only P-oxidation but also the hepatic secretion of triglycerides (Fig. 5) . The latter effect has been observed with several other drugs that severely inhibit the mitochondrial P-oxidation of fatty acids, including tetracyclines (20), perhexiline (4), or valproic acid (3). The latter compound inhibited the general transport of secretory vesicles in rat hepatocytes, decreasing not only the secretion of triglycerides but also that of serum albumin at the sinusoidal pole of hepatocytes, and the secretion of phospholipids, lysosomal components, and immunoglobulin A at their canalicular pole (3). These observations suggest that severe impairment of mitochondrial P-oxidation may secondarily impair vesicular transport (13). Hypothetically, the nonesterified fatty acids that accumulate in the liver might modify membrane structure and interfere with the association of coat, motor, or adaptor proteins with transport vesicles. Studies are in progress in our laboratory to assess these hypotheses.
Whatever the mechanism, the combination of decreased P-oxidation and decreased lipoprotein secretion after administration of glucocorticoids explains the steatogenic effect of these steroids in mice (Fig. 6B) The first P-oxidation cycle of long-chain fatty acids (which is mainly mediated by VLCAD and the trifunctional enzyme of the inner membrane) remains unimpaired, whereas those of medium-and short-chain fatty acids are inhibited. Impairment of both the mitochondrial P-oxidation of fatty acids and the hepatic secretion of lipoproteins explains the marked steatogenic effects of glucocorticoids in animals and humans.
